Zymedyne Therapeutics
PrivateLast Round
Seed
Nov 6, 2025
Total Funding Raised
$1.13M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Zymedyne Therapeutics is a biotechnology company that develops non-opioid, small-molecule treatments for chronic inflammatory and neuropathic pain.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Zymedyne Therapeutics Comparables
Compare Zymedyne Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Regulonix | 83% | |
| Centrexion Therapeutics | 77% | |
| Latigo Biotherapeutics | 74% | |
Zymedyne Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 6, 2025 | ||||
| Grant | Nov 6, 2024 | ||||
| Grant | Nov 1, 2024 | ||||
| Grant | Dec 15, 2023 | ||||
| Grant | Jun 3, 2022 | ||||
Grant | Jan 18, 2022 |
Key People
Founding team and executive leadership
Zymedyne Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Macquarie University Incubator | Grant |
| National Research Council Canada Industrial Research Assistance Program (NRC IRAP) | Grant |
| Alberta Innovates | Grant |
| Innovate Calgary | Grant |
| National Research Council of Canada | Grant |
| University of Calgary | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 6, 2025
$73K round led by University of Calgary
- Jan 18, 2022
$2K grant round led by Alberta Neuroscience
Zymedyne Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Zymedyne Therapeutics's valuation, stock price, and market status.